JACC:冠心病患者低舒张压与心绞痛呈相关性

2018-09-07 MedSci MedSci原创

在冠心病患者中,低舒张压与心梗发生风险增高相关,但其与心绞痛的关系尚不清楚。本研究目的旨在评估冠心病患者的低舒张压与心绞痛的相关性。本研究纳入了1259名心绞痛的门诊患者,并根据舒张压对其心绞痛频率进行评估。在所有冠心病患者中,共有411名(33%)在最初的一个月内有出现心绞痛,且在最低舒张压患者中比例更高(40 - 64 mm Hg: 37%)。在非调整模型中,心绞痛与舒张压呈J型相关(p =

在冠心病患者中,低舒张压与心梗发生风险增高相关,但其与心绞痛的关系尚不清楚。本研究目的旨在评估冠心病患者的低舒张压与心绞痛的相关性。

本研究纳入了1259名心绞痛的门诊患者,并根据舒张压对其心绞痛频率进行评估。在所有冠心病患者中,共有411名(33%)在最初的一个月内有出现心绞痛,且在最低舒张压患者中比例更高(40 - 64 mm Hg: 37%)。在非调整模型中,心绞痛与舒张压呈J型相关(p = 0.017),并当舒张压低于70-80mmHg时心绞痛的风险明显升高,这种相关性在经其他因素调整后仍然存在。

研究结果显示,在慢性冠心病患者中,低舒张压与心绞痛的发生呈相关性。


原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837561, encodeId=10e8183e561c3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 18 13:50:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854156, encodeId=f94c18541564b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 08 12:50:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323102, encodeId=feb81323102a7, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325963, encodeId=b2ca1325963ad, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447731, encodeId=e208144e7319e, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837561, encodeId=10e8183e561c3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 18 13:50:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854156, encodeId=f94c18541564b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 08 12:50:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323102, encodeId=feb81323102a7, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325963, encodeId=b2ca1325963ad, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447731, encodeId=e208144e7319e, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=)]
    2019-04-08 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837561, encodeId=10e8183e561c3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 18 13:50:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854156, encodeId=f94c18541564b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 08 12:50:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323102, encodeId=feb81323102a7, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325963, encodeId=b2ca1325963ad, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447731, encodeId=e208144e7319e, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837561, encodeId=10e8183e561c3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 18 13:50:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854156, encodeId=f94c18541564b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 08 12:50:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323102, encodeId=feb81323102a7, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325963, encodeId=b2ca1325963ad, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447731, encodeId=e208144e7319e, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837561, encodeId=10e8183e561c3, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Thu Apr 18 13:50:00 CST 2019, time=2019-04-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854156, encodeId=f94c18541564b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Apr 08 12:50:00 CST 2019, time=2019-04-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1323102, encodeId=feb81323102a7, content=<a href='/topic/show?id=80ca865895e' target=_blank style='color:#2F92EE;'>#舒张压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86589, encryptionId=80ca865895e, topicName=舒张压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325963, encodeId=b2ca1325963ad, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1447731, encodeId=e208144e7319e, content=<a href='/topic/show?id=523a3082670' target=_blank style='color:#2F92EE;'>#冠心病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30826, encryptionId=523a3082670, topicName=冠心病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=99445365987, createdName=liubm557, createdTime=Sun Sep 09 01:50:00 CST 2018, time=2018-09-09, status=1, ipAttribution=)]

相关资讯

盘点:JACC9月第一期研究一览

1. 双重抗血小板治疗评分(DAPT)遭质疑DOI: 10.1016/j.jacc.2018.06.023http://www.onlinejacc.org/content/72/10/1069双重抗血小板治疗(DAPT)评分对冠脉支架植入术后的DAPT及同时存在的缺血和出血风险有指导意义。本研究的目的旨在通过全国范围内的人群评估DAPT评分的表现。本研究纳入了2006年至2014年瑞典国家数

心血管疾病是中国人头号死因,专家:预防、康复应与治疗并重

心血管疾病是中国乃至全球的头号死因。在中国,心脑血管疾病引起的死亡占总死亡人数的40%,且患病率依然处于持续上升阶段。9月4日,在中国医学科学院阜外医院、德国北威州心脏和糖尿病中心、无锡明慈心血管病医院共同主办的“第三届中德医疗交流研讨会”上,澎湃新闻(www.thepaper.cn)记者获悉了上述消息。专家们认为,心血管病负担的日渐加重,无疑促使政府将治疗心血管疾病作为公共卫生的重中之重。但如

JAMA:保护好你的心血管!能使痴呆风险降低10%!

近日,法国波尔多大学的研究人员有了一项有趣的发现,保护心血管系统也许会有意外收获,大脑可以坐收渔翁之利!也就是说,要想保护大脑,先得保护好我们的心脏! 我们知道,合理饮食,运动和控制胆固醇是减少心脏病风险的有效措施。但是,你们知道吗?心血管问题很有可能会“迁怒”于大脑。狭窄,阻塞或渗漏的血管可导致中风,而中风恰恰是痴呆的第二大病因。 近日,法国波尔多大学开展了一项新的观察性研究,研究基

JACC:2017年美国血压指南推荐情况与心血管疾病风险

2017年美国心脏病学会(ACC/AHA)血压指南更新了抗高血压药物治疗的时机和强度。本研究的目的旨在比较和评估被2017 ACC/AHA指南推荐抗高血压治疗或不推荐的患者的心血管疾病发生风险。本研究纳入了REGARDS临床研究中的年龄≥45岁的患者,其中15179名患者接受有抗高血压治疗,14039名患者没有接受,并根据2017 ACC/AHA指南推荐将其分类,最终共有4094例心血管疾病事件(

JACC:2017年美国血压指南的1期高血压标准是否适用于中国?

血压在130-139/80-89mmHg被2017年美国心脏病学会(ACC/AHA)血压指南推荐为1期高血压,但是这种情况的血压在中国对心血管疾病风险的影响尚不清楚。 本研究纳入了来自中国多个省份的21441名年龄≥35岁的无基础心血管疾病的研究对象,其中1期高血压占25.8%。在35至39岁的人群中,1期高血压相比于血压小于120/80mmHg的心血管疾病风险HR为1.78 (95% [C

BMJ:双氯芬酸与心血管风险

由此可见,与未服药者、服用对乙酰氨基酚以及其它传统的非甾体类抗炎药相比,服用双氯芬酸会造成心血管健康风险。